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Background: TORS has become one of the latest surgical alternatives in the treatment of oropharynx squamous 
cell carcinomas (OPSCC) and has become increasingly accepted by surgeons as a treatment option. Surgical ro-
bots were designed for various purposes, such as allowing remote telesurgery, and eliminating human factors like 
trembling. The study aimed to compare systematic review of the available literature in order to evaluate the safety 
and efficacy of Transoral Robotic Surgery (TORS) compared with open surgery.
Material and Methods: We performed a systematic review of the available literature in order to evaluate the safe-
ty and effectiveness of TORS compared with open surgery. We compared TORS and open surgery based on 16 
outcomes divided in to 3 groups: intra-operative complications, post-operative complications, and functional and 
oncologic outcomes. An electronic search of observational studies was carried out using the following databases: 
MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, Cochrane Oral Health Group Trials Reg-
ister, and Scielo. Data analysis was carried out in accordance to Preferred Reporting Items for Systematic Reviews 
and Metanalysis (PRISMA) and the quality of the studies were evaluated using the Newcastle-Ottawa Scale. No 
language restrictions were imposed.
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experience, and the results are still not entirely convinc-
ing. Additionally, the CO2 laser used is not an ideal tool 
for haemostasis as, during the procedure, multiple alter-
nations are often required between the laser and a cau-
tery instrument. Also, the fact that the microscope and 
laryngoscopes provide a somewhat limited view of the 
oropharynx with low light; may result in some surgeons 
feeling like they are operating in a dark hole (2,11).
Transoral Robotic Surgery (TORS) has become one 
of the latest surgical alternatives in the treatment of 
OPSCC and has become increasingly accepted by sur-
geons as a treatment option (11). Surgical robots were 
designed for various purposes, such as allowing remote 
telesurgery, and eliminating human factors like trem-
bling (11). Since the introduction of robotic surgery in 
the field of surgery in 1985, it has been used in a range 
of surgical disciplines, such as orthopaedics, urology, 
radiosurgery, cardiac surgery and neurosurgery (12). 
Currently, there have been several institutional stud-
ies describing the TORS experience, but these multi-
centre data results are limited (1-3). Further review of 
the literature, carried out by the authors, reveals a lack 
of evidence when assessing the qualities of TORS and 
Open Surgery studies. This is especially apparent when 
assessing the rigorous outcomes. Consequently, we aim 
to compare and understand the impact of TORS against 
conventional open surgery. We will achieve this by car-
rying out a systematic review of the relevant literature 
comparing the two techniques.
Material and Methods
- Sources of Information and Development of Objective 
Questions
An electronic literature search was carried out by three 
reviewers (AR, RA & JLL) using various databases, in-
cluding: MEDLINE, EMBASE, Cochrane Central Reg-
ister of Controlled Trials, Cochrane Oral Health Group 
Trials Register and Scielo.
This study followed the PRISMA (Preferred Report-
ing Items for Systematic Review and Meta-Analyses) 
guidelines for a proper development of the systematic 
review and data analysed according to PICO (Patient, 
Intervention, Comparison and Outcome) (13).
Introduction
Over the last few years, the incidence of oropharynx 
squamous cell carcinomas (OPSCC) associated with 
the Human Papilloma Virus (HPV), is significantly in-
creasing (1-3). It is expected that if this rate of OPSCC 
growth continues, then by 2030 there will be at least 
twice as many annual cases in the U.S.A, compared to 
present (4). Open surgery still remains the most prefer-
able treatment option in terms of mobility and cosmetic 
impact (4). Adjuvant radiotherapy (RT) with lymphnode 
surgery, has been used for more than three decades, but 
it is associated with multiple complications and reduc-
tion in patients’ quality of life (QoL) (5,6).
Chemoradiotherapy (CRT) is no longer the first-line 
treatment of choice, due to the demographic changes that 
have occurred in patients with head and neck squamous 
cell carcinomas (HNSCC). The type of patient currently 
diagnosed ranges widely, from the elderly patient with a 
long history of tobacco consumption and alcohol abuse, 
to the younger and healthier patient with HPV-associ-
ated OPSCC, having no history of substance abuse and 
thus a better prognosis (1,7). Although patients treated 
with CRT avoid surgery-associated risks (namely an-
aesthetic complications, bleeding, postoperative pain, 
fistula formation, malocclusion, facial deformities and 
iatrogenic lesions in neurovascular structures), they are 
not entirely free from complications. For example, late 
complications such as xerostomia, osteoradionecrosis, 
mucositis, nephrotoxicity, neurotoxicity, ototoxicity, 
sepsis, pharyngeal and oesophageal stenosis, fibrosis 
in muscles involved in speech and swallowing, and the 
development of a second malignancy have all been re-
ported (2,4,8,9). Therefore, concerns about the toxicity 
of the treatment and late complications have become 
even more relevant, since these patients, given their age, 
potentially have a higher risk of developing late adverse 
effects (2).
Renewed interest in the search for a surgical approach 
for the treatment of OPSCC led to the introduction of 
Transoral Laser Microsurgery (TLM). In 2003, Steiner 
et al. (10) were the pioneers in publishing a series re-
garding this subject. TLM is a technically-challenging 
procedure, requiring specific training, a great deal of 
Results: From the 4 studies identified (Newcastle-Ottawa Scale mean score 6.5), 371 patients were revised (186 
patients were treated with TORS and 185 with conventional surgery). Overall, TORS, when compared with open 
surgery, appears to have better functional results (less hospital time, decannulation) and fewer intraoperative and 
post-operative complications. There is no significant difference when assessing the oncological outcomes (positive 
margins, survival rate) when comparing both techniques.
Conclusions: TORS has an overall better functional outcome, and less intraoperative and postoperative complica-
tions with no difference in positive margins and survival rate when compared with conventional therapy.
Key words: Transoral Robotic Surgery, TORS, open surgery, conventional surgery, head and neck cancer, oral 
cancer.
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- Screening process
The combination of control terms (MeSH and EM-
TREE) and key words were used wherever possible. 
The search terms used are listed below, where “[mh]” 
represented the MeSH terms and “[tiab]” represented a 
title and/or abstract: (“transoral robotic surgery” [mh] 
OR “TORS”[ti]) AND (open surgery [tiab]) OR (salvage 
surgery [tiab]) OR (conventional surgery [tiab]) AND 
(head and neck cancer [tiab]) OR (oral cancer [tiab]). 
In addition, a manual search was carried out of the 
journals related to head and neck oncology to ensure a 
thorough selection process. We applied no language re-
strictions. The references in the excluded articles were 
also checked by seeking studies that met the inclusion 
criteria. Articles published in the last 6 years, up to De-
cember 2019 were reviewed.
- Eligibility Criteria
The full papers and abstracts identified through the 
search engines were independently reviewed by the au-
thors (AR, RA & JLL) for inclusion in this systematic 
review. If there was a disagreement between the review-
ers, the authors reviewed the full text before reaching 
an agreement through discussion. Data extraction was 
then completed in duplicate by the same independent 
reviewers. The search strategy and the flow diagram of 
the article selection are shown in Fig. 1.
The articles that were included in this systematic re-
view met the following inclusion criteria: retrospec-
tive or prospective clinical observational studies, with 
50 or more human subjects and the clinical results of 
TORS in head and neck cancer were reported. Conse-
quently, several factors such as study design, number 
of patients included in the latest follow-up assessment, 
test/control groups, tumour size and TNM staging were 
studied. Furthermore, in order to address the aim of this 
study more comprehensibly, other technique-related pa-
rameters were also extracted, including operating time, 
blood loss, postoperative complications (e.g. Infection, 
bleeding, and respiratory tract oedema), functional out-
comes (e.g. duration of in-patient stay, and swallowing 
function) and oncological outcomes (average survival 
and disease-free average). By contrast, case reports or 
case series, studies comparing TORS with Chemora-
diotherapy (CRT), reviews, author debates, letters to the 
editor, pre-clinical studies, clinical studies involving 
animals or with deficient information were excluded.
- Quality of studies
The Newcastle-Ottawa Scale (NOS) was used to assess 
the quality of non-randomised studies (Case Controls & 
Cohorts Studies) by 5 reviewers (AR, XRL, AMR, EJS, 
JLL). Using a scoring system with stars, each study was 
judged on three broad aspects: the selection of study 
Fig. 1: PRISMA flow chart.
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groups, the homogeneity of the compared groups and 
the methodology of the results obtained (Table 1). If 
there was a disagreement between the reviewers, the 
authors would reach a consensus and decide the overall 
score.
Results
- Selection of articles
An initial assessment obtained 33 articles, of which 10 
were selected that were potentially relevant after eval-
uating their abstracts (1,3,6,9,14-19). The full texts of 
those 10 articles were then obtained. Of these, 4 articles 
(3,6,9,14) met the inclusion criteria and they were anal-
ysed qualitatively (Fig. 1).
- Results of the systematic review
The total number of patients studied was 371 (305 men 
and 66 women). 186 patients were treated with TORS 
and 185 with conventional surgery. With regard to the 
tumour staging, there were 118 cases of T1, 194 at T2, 
41 at T3 and 18 at T4. Regarding TNM staging, there 
were a total of 50 cases of TNM I, 60 cases of TNM II, 
50 cases of TNM III and 211 cases of TNM IV (Table 2).
Two of the articles (6,14) referred to the amount of blood 
lost during surgery, with a finding of a difference of 
over 200ml between the control group (open surgery) 
and the study group (TORS). 3 of the 4 articles (6,9,14) 
also discussed the operating times and a notable differ-
ence can be seen between the shortest times in the study 
group than in the control group. However, it should be 
mentioned that in the article by Lee et al. (9) there is a 
subgroup in the test group which had much longer in-
traoperative times due to the need to perform mandibu-
lectomy (Table 3).
Among the postoperative complications, it is noted that 
3 out of the 4 articles do not obtain statistically signifi-
cant results on the positive surgical margins, since the 
results of this are very similar between the two groups. 
Only the article by White et al. (6) obtained significant 
results, since the TORS group only had 6 cases of posi-
tive margins and the open surgery group had 19 cases. 
In terms of postoperative bleeding, the studies showed 
better results in the study group; Park et al. (14) ob-
tained 3.33% in the TORS group compared with 19.23% 
in the open surgery group and White et al. (6) obtained 
11% in the test group against 13% in the control group. 
With regards to postoperative fistulas, only two articles 
discussed these. The two studies had a very similar per-
centage of fistulas: 6% (6)  and 7.69% (14). However, 
in neither of the two studies do the fistulas occur in the 
TORS group, but in the open surgery group (Table 3).
As regards the functional results, it can be seen that 
TORS obtained significant results compared with open 
surgery (Table 4). The hospitalisation time varies a lot 
between the various studies, but among them all, the 
TORS group reveals a better result; 3.8 days (6), 26.1 
days (14)  and 14.6 days (9) against 8.0 days (6), 43.4 
days (14)  and 24.6 days (9), respectively. Tracheotomy 
cannot be assessed properly since not all study groups 
followed the same criteria - some studies performed it 
in advance (14) and others did not (6,9). However, in 
decannulation we observed that the TORS group ob-
tained much better results. Park et al. (14) took an aver-
age of 7.2 days to decannulate TORS patients and 15 
days in open-surgery patients. Likewise, Lee et al. (9) 
took an average of 5 days in the TORS group and 13.2 
in the control group. We can also observe that patients 
Author (year)
White et al. 
(2013)
Park et al. 
(2013)
Lee et al. 
(2014)
Ford et al. 
(2014)
SELECTION
1) Is the Case Definition Adequate? « « « «
2) Representativeness of the Cases - « « -
3) Selection of Controls - - - «
4) Definition of Controls « « « «
COMPARABILITY
1) Comparability of cases and controls on the basis of the 
design or analysis
« « « -
2) Comparability between patients in different treatment 
arms – main factor: Oncologic outcomes
3) Comparability between patients in Different treatmen 
arms – secondary factor: Postoperative complications 
EXPOSURE
1) Ascertainment of Exposure « « « «
2) Same method of ascertainment for cases and controls « « « «
3) Non-Response Rate « « « «
TOTAL QUALITY SCORE 6 7 7 6
Table 1: Quality assessment of selected studies based on Newcastle-Ottawa Scale.
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Author (year) White et al. (2013) Park et al. (2013) Lee et al. (2014) Ford et al. (2014)
Group (T/C)





128 56 57 130
64 64 30 26 27 30 65 65
16 14
Gender (M/F)
M: 48 M: 53 M: 30 M: 25 M: 21 M: 13 M: 12 M: 52 M: 51
F: 16 F: 11 F: 0 F: 1 F: 6 F: 3 F: 2 F: 13 F: 14
Age (SD) 61 ± NR 61 ± NR 66.6 ± 8.3 62.5 ± 12.1





T1: 25 T1: 23 T1: 10 T1: 2 T1: 10 T1: 6 T1: 0 T1: 21 T1: 21
T2: 34 T2: 29 T2: 13 T2: 14 T2: 12 T2: 9 T2: 11 T2: 36 T2: 36
T3: 2 T3: 9 T3: 3 T3: 6 T3: 5 T3: 1 T3: 3 T3: 6 T3: 6
T4: 3 T4: 3 T4: 4 T4: 4 T4: 0 T4: 0 T4: 0 T4: 2 T4: 2
N Category
N0: 37 N0: 34 N0: NR N0: NR N0: NR N0: NR N0: NR N0: 14 N0: 14




























N3: 1 N3: 0 N3: NR N3: NR N3: NR N3: NR N3: NR N3: 1 N3: 2
TNM Stage
I: 21 I: 15 I: 4 I: 0 I: 2 I: 0 I: 0 I: 4 I: 4
II: 10 II: 11 II: 5 II: 5 II: 4 II: 3 II: 2 II: 10 II: 10
III: 9 III: 13 III: 4 III: 2 III: 1 III: 0 III: 2 III: 7 III: 12
IV: 24 IV: 25 IV: 17 IV: 19 IV: 20 IV: 13 IV: 10 IV: 44 IV: 39
Table 2: Patients treated with the TORS technique an conventional technique according to Gender, Age, T Category, N Category, TNM Stage. 
C, group control; F, female; M, male; MA, mandibulotomy approach; NR, not reported; OS, open surgery; T, group test; TA, transoral approach; 
TORS; transoral robotic surgery.
Table 3: Patients treated with the TORS technique and conventional technique according to Intraoperative and Postoperative complications. 
BL, Blood loss; C, group control; F, female; IC, intraoperative complications; M, male; MA, mandibulotomy approach; Ml, millilitres; Min, 
minutes; NR, not reported; OT, operative time; OS, open surgery; PAE, postoperative airway edema; PB, postoperative bleeding; PF, postopera-
tive fistula; PI, postoperative infection; T, group test; TA, transoral approach; TORS; transoral robotic surgery.
Author 
(year) White et al. (2013) Park et al. (2013) Lee et al. (2014) Ford et al. (2014)
Group 








49ml 331ml 302.2ml 527.6ml NR NR NR NR NR
p-value <0.001 p-value 0.006 NR NR
OT






911.2 ± 320.6 
min.
48.3 ± 7.5 
min.
35.2 ± 9.3 
min.
75.5 ± 5.8 
min. NR NR
p-value <0.001 p-value <0.001 p-value <0.001 NR
PC
PI
6 (10%) 14 (22%) NR NR NR NR NR NR NR
p-value 0.03 NR NR NR
PF
0 (0%) 4 (6%) 0 (0%) 2 (7.69%) 0 (0%) 0 (0%) 0 (0%) NR NR
p-value 0.12 NR NR NR
PAE
13 (20%) 12 (19%) NR NR NR NR NR NR NR
p-value <0.99 NR NR NR
PB
7 (11%) 8 (13%) 1 (3.33%) 5 (19.23%) NR NR NR NR NR
p-value <0.99 NR NR NR
treated with TORS regained their swallowing abil-
ity much quicker; 8.4 (14) and 6.5 days (9) on average 
compared with 20.6 (14)  and 16.5 (9)  days in patients 
treated with open surgery.
With regards to the oncological results, 3 (3,9,14) out of 
the 4 articles (3,6,9,14)  do not show any significant re-
sults in terms of disease-free and survival time, and the 
differences between the test and control groups were 
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Author (year) White et al. (2013) Park et al. (2013) Lee et al. (2014) Ford et al. (2014)








C (OS) T 
(TORS) C(OS)
FO




5.9 days NR NR
p-value <0.001 p-value 0.045 p-value 0.001 NR
CA
TTS







p-value <0.001 NR NR NR
DE
NR NR 7.2 DAS 15 DAS 5.0 ± 1 DAS -
13.2 ± 6 
DAS NR NR
NR p-value <0.001 p-value <0.001 NR
FT
ATS 
23 (35%) 48 (75%) 30 (100%)
26 
(100%) 0 (0%) 0 (0%) 0 (0%) NR NR
p-value <0.001 NR NR NR
1YP
2 (3%) 20 (31%) 1 (3.33%)
3 
(11.54%) NR NR NR NR NR
p-value 0.002 NR NR NR
S (days) NR NR 8.4 days 20.6 days 6.5 ± 4 days
7.0 ± 8 
days
16.7 ± 5 
days NR NR
NR p-value <0.001 p-value <0.001 NR
OO
Follow-up (months) 24 24 36 36 24 24 24 36 36
Positive sur-
gical margins 6 (9%) 19 (29%) 3 (10%) 3 (12%) 1 (3.7%)
2 
(12.5%) 1 (7.1%) 10 (15%) 12 (18%)
p-value 0.007 p-value 0.999 p-value 0.682 p-value 0.52
Recurrence-
free survival 74% 43% 81% 76% 95.7% 91.6% 75% 73%
p-value 0.01 p-value 0.820 p-value 0.733 p-value 0.035
Overall 
survival 74% 43% 85% 78% 100% 96.7% NR NR
p-value 0.02 p-value 0.560 p-value 0.352 NR
Table 4: Patients treated with the TORS technique and conventional technique according to Functional and Postoperative complications. 1YP, 
1 year postoperative; ATS, At the time of surgery; C, group control; CA, cannulate; DAS, days after surgery; DE, Decannulated; F, female; 
FT, Feeding tube; FO; functional outcomes; FU(M), Follow-up (months); HD, hospital day; M, male; MA, mandibulotomy approach; NR, not 
reported; OO, Oncologic Outcomes; OS, open surgery; S, Swallowing; T, group test; TA, transoral approach; TORS; transoral robotic surgery; 
TTS, Tracheostomy use at the time of surgery.
very similar. Furthermore, the study by White et al. (6) 
shows significant results in both disease-free time (74% 
test group, 43% control group) and survival (74% test 
group, 43% control group) (Table 4).
- Quality of Studies
The Newcastle-Ottawa Scale (NOS) was used to anal-
yse the quality of observational studies and scores of 
between 6 and 7 were obtained (Table 1).
Discussion
The nature of treating head and neck cancer raises sev-
eral ethical reasons when conducting randomised clini-
cal trials. Consequently, evidence for TORS and open 
surgery to treat head and neck cancer is limited. As-
sessing the quality of observational studies allows us 
to address some of previous limitations. Although, we 
acknowledge the limitations commonly seen at cohort 
and case control studies selected for this study.
There are several methods to address the quality of 
evidence for observational studies such as ROBINS, 
Newcastle-Ottawa Scale (NOS), “Downs and Black” 
and “Scottish Intercollegiate Guidelines Network’s 
methodology checklist”. Although ROBINS has a has 
been highlighted, for its good validity (20), when as-
sessing surgical records NOS is  easy to apply (21), and 
has been widely used due to recommendations from the 
Cochrane Collaboration (22). Newcastle-Ottawa Scale 
(NOS) has been used in other systematic reviews to as-
sess TORS2 but has not yet been compared with open 
surgery. In order to provide similar methodology, as 
well as reveal the advantages previously mentioned, we 
agreed to use NOS.  However, we do acknowledge the 
limitations of NOS, when it is compared with ROBINS.
Treating HNSCC patients with surgery, instead of CRT, 
means they avoid the typical complications of RT and 
CT; xerostomia, osteoradionecrosis, mucositis, sepsis 
e605
Med Oral Patol Oral Cir Bucal. 2020 Sep 1;25 (5):e599-607. Robotic surgery vs open surgery for head and neck cancer
and trismus (2,4,9,23). A recent study (24)  reported an 
overall survival rate of 84.9% and a low rate of xero-
stomia in 442 patients who received intense modulated 
radiotherapy. However, Forastiere et al. (25) reported 
that toxicity increased by combining chemotherapy and 
radiotherapy, causing chronic lesions and severe fibro-
sis in the pharyngeal mucosa and masticatory mucosa. 
Whilst treating patients with surgery prevents them 
from experiencing complications of CRT, they are not 
free from complications. Some previous studies in-
dicate that almost 50% of patients who undergo open 
surgery for cancers of the head and neck develop post-
operative complications or problems with the healing of 
wounds (26).
Surgical complications of TORS include: formation of 
fistulas, postoperative haemorrhages, as well as surgi-
cal infections, pneumonia, nerve damage and lesions 
of the teeth (27). Two studies conducted at the Mayo 
Clinic (Rochester, MN, USA.) claim that their series 
of case studies resulted in 6% formation of fistulas 
(28,29). These patients underwent lymphadenectomy at 
the same time as TORS surgery. Fistulas were resolved 
with antibiotic treatment. Chia et al. (30) in a retrospec-
tive survey only had 0.2% of cases with fistulas in pa-
tients who received TORS, which is very close to the re-
sults of our review. As mentioned previously, only two 
studies (6,14) provided data regarding fistulas, but all 
instances occurred in cases of open surgery. None of the 
cases treated with TORS developed fistulas. Blood loss, 
prior chemotherapy and type of surgery are risk factors 
for postoperative infections and fistulas (31).
Postoperative haemorrhage is a potentially life-threat-
ening complication in patients treated with TORS. In 
the same study by Chia et al. (30) it is reported that, 
although the mortality rate after TORS was low (0.3%), 
haemorrhage was the causative factor in of all cases. 
Doazan et al. (32) reported 2 deaths because of post-
operative hemorrhage (1.6%).  This rate is higher than 
what was reported for the series of Mandal et al. (33) 
with 0.9% of severe hemorrhage that led to death. A 
total of 3.1% of postoperative haemorrhages were re-
ported which closely approximates the analysed study 
by Park et al. (14), which has a haemorrhage rate of 
3.3%, which are values that approximate a very recent 
published review, with a rate of 2.4% (34). However, 
some articles record values close to 6% (35) or even 
above 10%, such as the analysed study by White et al., 
with 11% or the multi-centre study by Aubry et al. (36) 
who reported18.5% of postoperative haemorrhages. As 
expected, Asher et al. (35) found that larger tumours 
have a greater bleeding risk than smaller tumours. An-
ticoagulant therapy and/or anti-platelet therapy was the 
only other risk factor identified in postoperative haem-
orrhages (35,36). Based on these results, additional data 
and larger samples are needed to obtain more accurate 
conclusions with regards to postoperative haemorrhag-
es. However, given the results of this review, intraopera-
tive bleeding is much less when using TORS than open 
surgery; but in postoperative bleeding there is not much 
difference between the two types of surgery and there is 
even a risk of death due to postoperative bleeding (30). 
While the surgical robot is an excellent tool to improve 
visualisation and instrumentation in the upper digestive 
tract, unfortunately, TORS can be less ideal for control-
ling haemorrhages after transoral robotic surgery. This 
reflection led Asher et al. (35) to perform preventive 
ligatures of the lingual artery. Improvements are being 
attempted in this respect, such as: the use of intraopera-
tive ultrasound images in real time to increase the 3D 
visualisation of the robotic system. Ultrasound imaging 
may allow the identification of the tumour boundaries 
and neurovascular structures, thus improving tumour 
resection and reducing morbidity (36).
TORS provides the ability to carry out, under a 3D-
HD view enlarged on multiple planes, en-bloc tumour 
resections, allowing the margins to be assessed more 
accurately during resections. The greater degree of in-
strumentation freedom, means that the safety margins 
of resections have results very similar to those of con-
ventional open surgery, but with a much lower cost in 
terms of surgical morbidity (37). Our systematic review 
confirms this, since out of the 4 articles analysed, 3 
showed no significant results regarding safety margins. 
Only the study by White et al. (6) reported significant 
results, resulting in 9% positive margins in the TORS 
group and 29% in the control group. The results on the 
safety margins are likely to have a direct proportional 
relationship to the overall survival rates of the disease 
and disease-free patients, since only the same study by 
White et al. (6) presents statistically significant results 
in these two sections. However, we must also note that 
the great difference between the results of White et al. 
(6) and those of the other 3 studies (3,9,14) on these two 
indices. The other 3 studies (3,9,14) obtained between 
76-96.7% in the control groups in these indices and the 
study by White et al. (6) only obtained 43%, in both the 
patient survival rate and in disease-free time in the open 
surgery group. One explanation could be that the TORS 
group only had 5 patients with T3 or T4, while the open 
surgery group had a total of 12 patients. The larger the 
tumour, the higher the rate of positive margins.
A multi-centre study (38), with 410 patients, who were 
treated with TORS, obtained loco-regional control rates 
of 91.2% at 24 months and of 88.8% at 36 months. The 
results of this study are very similar to the results ob-
tained by the studies analysed in this review, reinforc-
ing the idea the TORS has high rates of survival and 
disease-free patients.
From a functional point of view, many clinical studies 
have shown an improved swallowing function in pa-
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tients treated with TORS, compared with other surgical 
methods and even compared with primary chemother-
apy. They also show a much shorter hospital stay and 
faster recovery (27). In terms of function we can state 
that TORS demonstrates more beneficial results than 
open surgery. All of the studies analysed obtained sig-
nificant results in the reduction of time spent in hospital 
and in the better swallowing ability of patients treated 
with TORS.
Another aspect to be noted is the cost-effectiveness 
analysis of TORS versus open surgery. Dombrée et al. 
(39) compared TORS, TLM and open surgery for partial 
and total laryngectomies. Interestingly enough, TLM 
and open surgery obtained better results against TORS; 
maybe a reason for these results is the high initial in-
vestment needed for TORS. Another recent article (40) 
concluded that TORS cost are 24-35% less than IMRT, 
but that one of the reasons why TORS costs could in-
crease is the adjuvant therapy as de Almeida et al. (38) 
explains. Spellman et al. (40) concluded that TORS is 
highly cost-effectiveness is early stage oropharyngeal 
cancer.
One of the limitations of the analysed studies is that 
they are rather heterogeneous with one another: Ford et 
al. (3) and White et al. (6) studied salvage surgery for 
OPSCC while Park et al. (14) studied salvage surgery, in 
hypopharyngeal SCC, and Lee et al. (9) studied only T1-
T3 in tonsillar cancer. Results of this systematic review 
should therefore be analysed with caution. The multiple 
co-founders, which are difficult to control outside of a 
clinical trial, should be taken into account and conse-
quently the level of evidence should be interpreted as 
limited.
Conslusions
In conclusion, TORS appears to be a promising tech-
nique with fewer complications compared with open 
surgery. Its effectiveness depends on the location of the 
tumour, for which more specific studies of each type of 
cancer are needed. The skill of the surgical team also 
has an effect, since the training curve is relevant. TORS 
obtains much better functional results when compared 
with Open Surgery therapeutic techniques for treating 
patients with HNSCC. Although the oncological out-
comes of TORS are good, they do not appear better than 
those of open surgery.
We suggest that more high quality observational stud-
ies, to understand the effectiveness of TORS when com-
pared with Open Surgery, are needed. The studies will 
need to use good statistical power and standardised out-
come measures to obtain actuate results.
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